AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Mustang Bio, Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00FXTN439
0.37▲ 0.00 (0.22%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.37
Day's Range
0.36 – 0.39
52-Week Range
0.36 – 1.52
Volume
17.6K
Avg Volume
37.1K
Share Statistics
Shares Outstanding
Employees
4
Exchange
XNAS
Listed
2017-08-22
Share count as of August 6, 2026

Mustang Bio, Inc. (MBIO) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Mustang Bio, Inc. (MBIO)
What is Mustang Bio, Inc.'s Market Cap?
Mustang Bio, Inc.'s Market Cap is $2.7M, based on as-reported figures from SEC (XBRL) filings.
What is Mustang Bio, Inc.'s Enterprise Value?
Mustang Bio, Inc.'s Enterprise Value is -$12.5M, based on as-reported figures from SEC (XBRL) filings.
What is Mustang Bio, Inc.'s EV / EBITDA?
Mustang Bio, Inc.'s EV / EBITDA is 3.5×, based on as-reported figures from SEC (XBRL) filings.
What is Mustang Bio, Inc.'s Net Income (TTM)?
Mustang Bio, Inc.'s Net Income (TTM) is -$3.0M, based on as-reported figures from SEC (XBRL) filings.
What is Mustang Bio, Inc.'s EBITDA?
Mustang Bio, Inc.'s EBITDA is -$3.5M, based on as-reported figures from SEC (XBRL) filings.
What is Mustang Bio, Inc.'s Diluted EPS (TTM)?
Mustang Bio, Inc.'s Diluted EPS (TTM) is -0.42, based on as-reported figures from SEC (XBRL) filings.
What is Mustang Bio, Inc.'s Net Debt?
Mustang Bio, Inc.'s Net Debt is -$15.2M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · MBIOAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income:
Interest income, net
Total other income
Net Loss
Net loss per Class A common and common shares outstanding, basic
Net loss per Class A common and common shares outstanding, diluted